Evidence map›Paper›PMID 28337280›Full record

ArticleAmerican journal of translational research2017

MiR-15a suppresses hepatocarcinoma cell migration and invasion by directly targeting

Bo Liu, Ting Sun, Gang Wu, Hui Shang-Guan, Zhao-Jin Jiang, Ji-Ren Zhang, Yan-Fang Zheng

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis.International journal of molecular sciences · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Bo LiuOncology Center, Zhujiang Hospital of Southern Medical University Guangzhou 510282, Guangdong, China.
Ting SunOncology Center, Zhujiang Hospital of Southern Medical University Guangzhou 510282, Guangdong, China.
Gang WuOncology Center, Zhujiang Hospital of Southern Medical University Guangzhou 510282, Guangdong, China.
Hui Shang-GuanDepartment of Oncology, Foshan Hospital, Southern Medical University Foshan 528000, Guangdong, China.
Zhao-Jin JiangOncology Center, Zhujiang Hospital of Southern Medical University Guangzhou 510282, Guangdong, China.
Ji-Ren ZhangOncology Center, Zhujiang Hospital of Southern Medical University Guangzhou 510282, Guangdong, China.
Yan-Fang ZhengOncology Center, Zhujiang Hospital of Southern Medical University Guangzhou 510282, Guangdong, China.
Zhujiang Hospital · CNFoshan Maternity and Child Health Care Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to determine the function of miR-15a in HCC, and identify

methodsRNA expression was evaluated by quantitative real-time PCR (qRT-PCR). The effects of miR-15a or

resultsMiR-15a was markedly downregulated in sphere culture HCC cells by qRT-PCR.

conclusionMiR-15a could suppress HCC progression through the repression of

Indexed as

cMybHepatocarcinomaMiR-15a

Identifiers

PMID28337280
PMCPMC5340687
OpenAlexW2996875660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.